CheckMate 017, 2015 NCT01642004
nivolumab alone (n=135) vs. docetaxel (n=137)
randomized controlled trial
Nivolumab
nivolumab, at a dose of 3 mg per kilogram of body weight every 2 weeks, Reductions in the nivolumab dose were not permitted.
Docetaxel
docetaxel, at a dose of 75 mg per square meter of body-surface area every 3 weeks
squamous - mNSCLC - L2 - all population
no information about EGFR or ALT status
open label
NA
P3/ two sided and one interim analysis. Hierarchical testing procedure with secondary endpoints
IA results (stopped) / this trial meet its primary endpoint of OS and secondary endpoint ORR and PFS